Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease). The peptide is also under evaluation for potential prophylactic therapeutic benefits as well.
HT-002 is at the preclinical stage of development.
May 20, 2020 Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic
![]() |